A clinical study that began in a research unit in Gqeberha (PE), Eastern Cape, has transformed global treatment of drug-resistant tuberculosis.

Please provide your email address to receive an email when new articles are posted on . The CDC, IDSA and other agencies created updated guidance for treating drug-susceptible and drug-resistant TB.

A clinical trial published in the New England Journal of Medicine showed that the oral antibiotic levofloxacin taken once-daily for six months substantially reduced the risk of developing ...

🛍️ Amazon Prime Day: The best deals chosen by our editors 🛍️ By Laura Baisas Published Jan 29, 2025 5:00 PM EST Add Popular Science (opens in a new tab) More information Adding us as a Preferred ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Tuberculosis (TB), one of the leading infectious disease killers ...

A new study uncovers vulnerabilities in drug-resistant TB, offering hope for improved treatments. Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works ...

Tuberculosis (TB) remains a global health challenge, affecting millions each year. In 2023, an estimated 10.8 million people contracted TB, with 1.25 million deaths, according to the World Health ...

Tuberculosis is both curable and preventable, yet each year, it still kills more people than any other infectious disease. One reason is that current treatments hinge on rifampicin, an antibiotic that ...

Some patients with highly drug-resistant tuberculosis could benefit from a shorter treatment with fewer drugs, while others may warrant more aggressive therapy, according to the findings of a new ...

A clinical trial published in the New England Journal of Medicine showed that the oral antibiotic levofloxacin taken once-daily for six months substantially reduced the risk of developing ...

Protocol can be used in children and pregnant women ...